MDxHealth SA
NASDAQ:MDXH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MDxHealth SA
Cash from Operating Activities
MDxHealth SA
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Cash from Operating Activities
-$2.2m
|
CAGR 3-Years
60%
|
CAGR 5-Years
36%
|
CAGR 10-Years
17%
|
|
|
Galapagos NV
AEX:GLPG
|
Cash from Operating Activities
-€257.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Oxurion NV
XBRU:OXUR
|
Cash from Operating Activities
-€1.4m
|
CAGR 3-Years
63%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Cash from Operating Activities
-€6.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
European Medical Solutions
XBRU:ALEMS
|
Cash from Operating Activities
€5.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MDxHealth SA
Glance View
MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
See Also
What is MDxHealth SA's Cash from Operating Activities?
Cash from Operating Activities
-2.2m
USD
Based on the financial report for Dec 31, 2025, MDxHealth SA's Cash from Operating Activities amounts to -2.2m USD.
What is MDxHealth SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
17%
Over the last year, the Cash from Operating Activities growth was 88%. The average annual Cash from Operating Activities growth rates for MDxHealth SA have been 60% over the past three years , 36% over the past five years , and 17% over the past ten years .
